This triple masked crossover clinical trial comprised 60 prepubescent obese children, either female or male and aged 6-10 years. They were randomly selected from among children referred to the Pediatric Obesity & Metabolic Syndrome Clinic of the Pediatric Preventive Cardiology, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences. The objective of study was to determine the probable therapeutic features of zinc supplementation on metabolic syndrome profiles and markers of inflammation and oxidation. Firstly, demographic data as well as weight, height, waist circumference and blood pressure were registered in questionnaire for each patient. Fasting blood samples were taken from patients and were analyzed for serum zinc, fasting blood sugar, insulin level, lipid profile, apolipoproteins A & B, leptin, malonyl dialdehyde and CRP. Then, children were randomized into two groups of equal number. For a period of 8 weeks, Group A received 20 mg Zinc Sulfate tablets and Group B took placebo. Drug and placebo were delivered in similar shapes and packs. After two months, we provided another blood exam of patients to detect changes. Following a 4-week wash out period, placebo and zinc replaced between groups, in other word, group A took placebo and group B received zinc tablets. In addition to baseline study, physical examination and biochemical tests were repeated at all stages of the trial and were analyzed to verify the authenticity of our hypothesis.